PTC Therapeutics (PTCT) Misses Q3 EPS by 12c

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.27), $0.12 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $9.78 million versus the consensus estimate of $9.88 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• CRH plc (CRH) PT Lowered to $135 at UBS, Buy Rating Maintained
• Thor Industries (THO) Misses Q4 EPS by 13c